HomeAI · summaries
Storia in 9 fonti
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
- ·
benzinga.com
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
- ·
economictimes.indiatimes.com
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The…
- ·
cnbc.com
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
- ·
endpoints.news
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.
- ·
milanofinanza.it
Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News
L’operazione consente al gruppo farmaceutico di mettere le mani su BPL-003, uno spray nasale a base di DMT in fase 3 di sperimentazione per la depressione resistente. Le azioni di…
- ·
statnews.com
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
- ·
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes…
- ·
forbes.it
Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari
Eli Lilly acquisisce AtaiBeckley per 2,8 miliardi di dollari per sviluppare trattamenti contro la depressione resistente
- ·
axios.com
Eli Lilly agrees to $3.8B psychedelic buy
The AtaiBeckley acquisition would be the largest psychedelic deal to date.
- ·
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
- ·
Eli Lilly lancia opa su AtaiBeckley | MilanoFinanza News
<p>Eli Lilly e AtaiBeckley, azienda biofarmaceutica in fase clinica quotata al Nasdaq che sviluppa terapie innovative per le patologie mentali, hanno raggiunto un accordo per…